pendulum glp-1 review Probiotic This statement has not been evaluated by the Food Pendulum GLP-1 Probiotic Pro

Merck, Roche, AstraZeneca, and Lilly all rose in the rankings with Lilly pushing GSK out of the top 10

Reduced Eating Frequency Patients using GLP-1s for chronic weight management commonly eat less and may eat less frequently

Alternative GLP-1 formulations, dose adjustments, or switching to different weight loss medications may be appropriate

RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies

Top Product Forecasts for 2024 [1] NO

The company enjoyed growth from key drivers including Vabysmo (faricimab), launched in 2022 for ophthalmology indications including wet age-related macular degeneration